Vancomycin-resistant Staphylococcus aureus in a bone marrow transplantation unit

Mabed, Mohamed; Marouf, Samy

doi:10.1007/s00277-004-0968-2

Cited by 3 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although staphylococcal bacteremia due to vancomycin‐resistant isolates in allogeneic HSCT recipients has been reported worldwide (22), all S. epidermidis and S. haemolyticus blood isolates tested in the present study were still susceptible to vancomycin even when considering the decreased breakpoint of 2 mg/L (17). Similar to previous susceptibility investigations against S. epidermidis in Austria, we observed in vitro resistance to fosfomycin in >40% of all CNS isolates which was not limited to methicillin‐resistant CNS strains.…”

Section: Discussionmentioning

confidence: 70%

In vitro activity of daptomycin and tigecycline against coagulase‐negative staphylococcus blood isolates from bone marrow transplant recipients

Kratzer

Rabitsch

Hirschl

et al. 2007

European J of Haematology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 70%

In vitro activity of daptomycin and tigecycline against coagulase‐negative staphylococcus blood isolates from bone marrow transplant recipients

Kratzer

Rabitsch

Hirschl

et al. 2007

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…The first VISA in the US was reported in 1997 [47] and the second [42] and third cases were reported in 1999 [67,68] [71] and in a retrospective evaluation from the US Veterans Affairs Medical Centers [45]. Additionally, France [72], Australia [73][74][75], Greece [43], Thailand [76], Singapore [77], Italy [78] and Egypt [79] have in total published > 20 VISA cases since July 1996, illustrating the worldwide existence of this trend.…”

Section: Staphylococcus Aureus With Intermediate Susceptibility To Vamentioning

confidence: 94%

Vancomycin for treatment of invasive, multi-drug resistantStaphylococcus aureusinfections

Pope¹,

Roecker

2007

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Staphylococcus aureus is a bacterial pathogen responsible for a variety of serious infections and is a frequent cause of nosocomial disease. During the last 60 years, S. aureus has developed increasing in vitro resistance to virtually all antimicrobials. In contrast, vancomycin has maintained a high degree of activity in vitro against this pathogen, although slight changes with in vitro activity could vastly change clinical activity. As a result, vancomycin has become the mainstay of therapy for invasive infections due to methicillin-resistant strains. However, clinical strains of S. aureus with intermediate resistance to vancomycin were reported in 1996, followed in 2002 with reports of isolates that were fully resistant. Although many authorities believe vancomycin remains the drug of choice for most staphylococcal-resistant infections, important issues surrounding its clinical application remain. These include the need for multiple daily dosing, intravenous administration, requirements for serum concentration monitoring, increasing resistance in vitro, modest efficacy rates and (less frequently) treatment-limiting adverse effects. This review addresses these important topics.

show abstract

Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis

Shariati

Dadashi

Moghadam

et al. 2020

Sci Rep

184

126

View full text Add to dashboard Cite

Vancomycin-resistant Staphylococcus aureus (VRSA), Vancomycin-intermediate S. aureus (VISA) and heterogeneous VISA (hVISA) are subject to vancomycin treatment failure. The aim of the present study was to determine their precise prevalence and investigate prevalence variability depending on different years and locations. Several international databases including Medline (PubMed), Embase and Web of Sciences were searched (data from 1997 to 2019) to identify studies that addressed the prevalence of VRSA, VISA and hVISA among human clinical isolates around the world. Subgroup analyses and meta-regression were conducted to indicate potential source of variation. Publication bias was assessed using Egger’s test. Statistical analyses were conducted using STATA software (version 14.0). Data analysis showed that VRSA, VISA and hVISA isolates were reported in 23, 50 and 82 studies, with an overall prevalence of 1.5% among 5855 S. aureus isolates, 1.7% among 22,277 strains and 4.6% among 47,721 strains, respectively. The overall prevalence of VRSA, VISA, and hVISA before 2010 was 1.2%, 1.2%, and 4%, respectively, while their prevalence after this year has reached 2.4%, 4.3%, and 5.3%. The results of this study showed that the frequency of VRSA, VISA and hVISA after 2010 represent a 2.0, 3.6 and 1.3-fold increase over prior years. In a subgroup analysis of different strain origins, the highest frequency of VRSA (3.6%) and hVISA (5.2%) was encountered in the USA while VISA (2.1%) was more prevalent in Asia. Meta-regression analysis showed significant increasing of VISA prevalence in recent years ( p value ≤ 0.05). Based on the results of case reports (which were not included in the calculations mentioned above), the numbers of VRSA, VISA and hVISA isolates were 12, 24 and 14, respectively, among different continents. Since the prevalence of VRSA, VISA and hVISA has been increasing in recent years (especially in the Asian and American continents), rigorous monitoring of vancomycin treatment, it’s the therapeutic response and the definition of appropriate control guidelines depending on geographical regions is highly recommended and essential to prevent the further spread of vancomycin-resistant S. aureus .

show abstract

Vancomycin-resistant Staphylococcus aureus in a bone marrow transplantation unit

Cited by 3 publications

References 17 publications

In vitro activity of daptomycin and tigecycline against coagulase‐negative staphylococcus blood isolates from bone marrow transplant recipients

In vitro activity of daptomycin and tigecycline against coagulase‐negative staphylococcus blood isolates from bone marrow transplant recipients

Vancomycin for treatment of invasive, multi-drug resistantStaphylococcus aureusinfections

Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis

Contact Info

Product

Resources

About